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HPR6 MUTANTS AND USES THEREOF

comprising a nucleotide sequence encoding Hpr6-mut,
Wherein the Hpr6-mut is expressed in said tumor. In a

preferred embodiment the anti-cancer agent is doxorubicin.

FIELD OF THE INVENTION

In another aspect of the invention there is provided a
method of enhancing the effect of a Cyp3A4 metaboliZable

The invention relates to Hpr6 mutants and their use. In
particular, the present invention relates to the use of the

anti-cancer agent in a non-sarcoma tumor of a patient

human Hpr6 protein as a target for development of anti

comprising administering to the patient a replication defec

cancer drugs, as Well as adenoviral vectors encoding a

tive adenovirus vector comprising a nucleotide sequence

mutant Hpr6 for use in anti-cancer therapy.

encoding Hpr6-mut; and administering the Cyp3A4 metabo
liZable anti-cancer agent to the patient, Wherein the Hpr6

BACKGROUND OF THE INVENTION

mut is expressed in said tumor. In a preferred embodiment

the anti-cancer therapeutic agent is administered Within
Therapeutic treatments for solid tumors usually include a
combination of DNA damaging agents, including a class of

about one to about tWenty four hours of administration of the
adenoviral vector.

compounds that are metabolized by the CYP3A4 protein.
These DNA damaging agents include topoisomerase inhibi

screening test agents comprising contacting cells that over

In another aspect of the invention there is a method of

tors, and doxorubicin or adriamycin, Which is an anthracy
cline antibiotic that is frequently used in combination With
other drugs for treating breast cancer. Doxorubicin acts

through multiple mechanisms that include intercalating
Within DNA, binding to topoisomerase II, and generating

express Hpr6 With the test agents and doxorubicin or other

20

Cyp3A4 metaboliZable anti-cancer agent are identi?ed as

reactive oxygen species. The effectiveness of doxorubicin
or topoisomerase inhibitor-based chemotherapy is limited
by drug resistance. For example, doxorubicin resistance can

emerge through alterations of proteins regulating the avail
ability, activation, or inactivation of the drug, through
changes in topoisomerase II, or through changes in path
Ways mediating DNA repair and apoptosis. The proteins that
cause chemotherapeutic resistance are potential therapeutic
targets for cancer, and inhibiting these proteins could lead to
improved effectiveness of doxorubicin and other compounds
that are metabolized by Cyp3A4.
Hpr6 is a member of the heme-1 domain family of

proteins, Which includes the human Hpr6 and Dg6 proteins,
the rodent 25-Dx and IZAg proteins, and the budding yeast
Dap1p protein. The Hpr6/25-Dx/IZAg/Dap1p proteins are
relatively small (approximately 25 kDa) and are composed

anti-Hpr6 agents.
BRIEF DESCRIPTION OF THE DRAWINGS
25

FIG. 1 shoWs that Hpr6 is expressed in breast cancer cell
lines and is induced by doxorubicin. 1A: Western blot

analysis shoWing expression of Hpr6 (top panel) and tubulin
30

(bottom panel) in the cell lines BT549 (lane 1), MCF-7 (lane
2), HCT-100 (lane 3), MDA-MB-231 (lane 4), MDA-MB
435 (lane 5), and HeLa (lane 6). Hpr6 migrates as a 27 kDa

protein. The position of molecular Weight markers is indi
35

cated to the left. 1B: Hpr 6 expression is induced after
treatment With doxorubicin and camptothecin. MDA-MB
231 cells Were untreated (upper panel, lane 1), treated With
0.5 or uM doxorubicin (upper panel, lanes 2 and 3), or 0.25

1 um camptothecin (upper panel, lane 4) for 3 days, and the
expression of Hpr6 Was analyZed by Western blot. Hpr6

largely of a central heme-1 domain that shares homology

With cytochrome b5. Like cytochrome b5, the IZAg protein
binds to heme. Dap 1 p damage resistance protein, 7) Was
previously identi?ed in Saccharomyces cerevisiae, a model

Cyp3A4 metaboliZable anti-cancer agent; Wherein test
agents that result in enhanced cell death compared to Hpr6
overexpressing cells that are contacted With only the

40

expression Was elevated sharply by exposure to the tWo
drugs as indicated by the fold increase indicated beloW the
upper panel. Tubulin is included as a control for equal

organism for studying chemotherapeutic resistance. Yeast

protein loading (loWer panel).

mutants lacking Dap 1 p exhibit extreme sensitivity to a
DNA alkylating agent and are moderately sensitive to

of an inactive form of Hpr6. 2A: Puri?cation of GST-Hpr6

hydroxyurea and radiation (Hand R A et al., Eukaryolic Cell

FIG. 2. The Ad-Hpr6-mut adenovirus directs expression
45

useful for treating cancer. Drug resistance is one of the
primary causes underlying failure of treatment for cancer,
and there is a profound need to screen for inhibitors of the

(lane 1) and GST-Hpr6-mut (lane 2) fusion proteins. Pro
teins Were puri?ed using glutathione-agarose and analyZed
by SDS-PAGE electrophoresis. 2B: Heme binding by Hpr6
(left column) but not Hpr6-mut (right column). SolubiliZed

2003; 2: 121-32).
Thus, drugs that target the Hpr6 protein are potentially
50

Hpr6 pathWay.

proteins Were analyZed for absorbance at 400 nm, and
measurements Were performed in triplicate. 2C: Western blot
analysis of MDA-MB-231 cells infected With 500, 1000, or

2000 pfu/cell of Ad-Hpr6-mut (lanes 1-3) or 2000 pfu/cell of
SUMMARY OF THE INVENTION
In one aspect of the invention there is provided a mutant

Ad-LacZ (lane 4). Hpr6 expression Was visualiZed With an
antibody to the HA epitope tag. D. The Hpr6-mut protein is
55

overexpressed compared to endogenous Hpr6 folloWing

Hpr6 polypeptide (Hpr6-mut) consisting of the amino acid

Ad-Hpr6-mut infection. MDA-MB 231 cells Were infected

sequence SEQ ID NO:1.
In another aspect of the invention there is provided an

With Ad-LacZ (lane 1) or Ad-Hpr6-mut (lane 2) and ana

lyZed by Western blots probed for HA (top panel), Hpr6
(middle panel), or tubulin (bottom panel). The positions of

isolated nucleic acid encoding Hpr6-mut.
In another aspect of the invention there is provided a

60

the exogenous Hpr6-mut and endogenous Hpr6 protein are
indicated in the center panel (top and bottom, respectively).
FIG. 3. Ad-Hpr6-mut acts synergistically With doxorubi
cin to induce cell death. 3A: graph shoWing viability of

65

Ad-Hpr6-mut (dashed line), combined With increasing con
centrations of doxorubicin Qi axis). Viability Was measured
by MTT assay. 3B: graph shoWing viability of MDA-MB

vector encoding Hpr6-mut. In preferred embodiments, the
vector is an adenoviral vector, most preferably a replication
de?cient adenoviral vector; or a plasmid.
In a further aspect of the invention there is provided a
method for treating a non-sarcoma tumor comprising admin
istering to a patient an anti-cancer agent that is metaboliZed

by Cyp3A4 and a replication defective adenovirus vector

MDA-MB-231 cells infected either Ad-LacZ (solid line) or

US 7,342,100 B2
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231 cells infected either Ad-LacZ (solid line) or Ad-Hpr6
mut (dashed line), combined With 0-41 uM doxorubicin Qi
axis). Viability Was measured by trypan blue assay. 3C:
graph showing viability of MDA-MB-231 cells treated With
1 uM doxorubicin combined With increasing doses of either

proteins that bind to progesterone and regulate its metabo
lism; (b) the rat 25-Dx protein is up-regulated in liver tumors
induced by dioxin; and (c) breast cancer cells engineered to
overexpress Hpr6 are hypersensitive to oxidative damage
(Hand R A and Craven R J. Journal of Cellular Biochemistry
2003; 90: 534-47). HoWever, fundamental questions such as
the localiZation of Hpr6, its expression in cancer, and its
biochemical activities have not been previously reported.
To test the role of Hpr6 in resistance to chemotherapeutic

Ad-LacZ (solid line) or Ad-Hpr6-mut (dashed line). Viabil
ity Was measured by MTT assay. D, graph shoWing viability
of MDA-MB-231 cells infected either Ad-LacZ (solid line)

or Ad-Hpr6-mut (dashed line), combined With increasing
concentrations of camptothecin Qi axis). For all of the

agents, an efficient means of inhibiting Hpr6 in tumors Was

developed, and the ability of cells With inhibited Hpr6

assays, error bars represent the standard deviations of trip
licate measurements and the results shoWn are representative

function to respond to damage Was tested. Breast cancer
cells Were infected With an adenovirus bearing a dominant

of at least three independent experiments.
FIG. 4. Hpr6-mut induces cell death, but does not alter
doxorubicin localization. 4A: Morphology of MDA-MB
231 cells infected With Ad-LacZ (left panel) or Ad-Hpr6-mut
(right panel) and treated With 1 uM doxorubicin for 72
hours. Ad-Hpr6-mut-infected, doxorubicin-treated cells
generally had a rounded or necrotic morphology. 4B: Hpr6
mut does not alter the localiZation or short-term accumula
tion of doxorubicin. MDA-MB-231 cells Were infected With

20

negative mutant of Hpr6 and treated With doxorubicin and
other anti-cancer agents. It is shoWn herein that expression
of mutant Hpr6 triggers cell death folloWing anti-cancer
agent therapy, such as for example doxorubicin therapy or
other anti-cancer agents that are metaboliZed by Cyp3A4.
This suggests that Hpr6 might function in tumors to promote
chemotherapeutic resistance. It is also shoWn that Hpr6 is
overexpressed in approximately half of clinical breast tumor

either Ad-LacZ (left panels) or Ad-Hpr6-mut (right panels)

samples. Together, these ?ndings indicate that Hpr6 medi

and treated With 10 uM doxorubicin for 1 hour. Cells Were

ates resistance to chemotherapeutic agents in cancer cells
and is a target for therapeutic intervention.

then ?xed and visualiZed using bright-?eld microscopy (top
panels) or ?uorescence (bottom panels). In both groups of
infected cells, doxorubicin accumulated in the nucleus to

25

similar extents. These results Were con?rmed by F ACS

analysis (data not shoWn).
FIG. 5. Hpr6 overexpression in clinical breast tumor

samples. 5A: Western blot analysis of Hpr6 expression in
paired normal (N, odd lanes) and tumor (T, even lanes)
samples from the same patients (lanes 1-6). Hpr6 Was
overexpressed in tumors from patients 1 and 3. B, Hpr6
overexpression in unmatched breast tumor samples. Hpr6
expression Was high in tumors from 4 separate patients

heme binding sensitiZes metastatic cancer cells to chemo
30

therapeutic agents, in particular Cyp3A4 metaboliZable
compounds. The role of Hpr6 in cancer has not been

examined previously, and these results demonstrate that
Hpr6 function in normal cells is corrupted in tumors cells to

yield improved resistance to chemotherapeutic agents, e.g.,
35

etoposide (ETP), adriamycin (doxorubicin: DOX), taxol,

40

paclitaxol and irinotecan (CPT-ll) and other Cyp3A4
metaboliZable anti-cancer agents for example.
There is a precedent for Hpr6 homologues directing
resistance to DNA damaging agents, because the Hpr6 yeast
homologue is required for resistance to the methylating

(lanes 1, 3, 5, and 6).
FIG. 6. Hpr6 localiZes to the perinuclear region in MCF-7
breast cancer cells. MCF-7 cells Were transfected With the

control plasmid pBK-CMV (panels 1 and 2) or the Hpr6

expression plasmid pBK-Hpr6 (panels 3-6) and isolates

The studies disclosed herein demonstrate that; (i) Hpr6 is
overexpressed in breast tumors; and (ii) Hpr6 binds to heme
and localiZes to the endoplasmic reticulum; and (iii) an
inactive mutant of the Hpr6 protein Which inhibits Hpr6

Were selected that stably expressed Hpr6 (ref. 13). Cells

agent MMS and plays a minor role in resistance to radiation

Were plated on 4-Well chamber slides and analyZed by bright

(Hand R A et al. Eukaryolic Cell 2003; 2: 121-32). There is
also a precedent for Hpr6 homologues regulating metabo
lism, because the rodent Hpr6 homologue increases
hydroxylation of progesterone, a key step in its metabolism

?eld microscopy (panels 1, 3, and 5) or by immuno?uores
cence after staining With an antibody directed to HA (panels

2, 4, and 6). Panels 1-4are at 100x resolution, While panels

45

(Min L et al. Mol Cell Endocrin 2004; 215: 143-8). Our

5 and 6 are at 400x.

results suggest that the effects of Hpr6 on xenobiotic com

FIG. 7. The amino acid sequence (SEQ ID NO:1) and

corresponding nucleotide sequence (SEQ ID NO:2) of Hpr6
mut are shoWn. The heme binding region (SEQ ID NO:3) is

highlighted by underlining. In Hpr6-mut, the aspartic acid

50

(D) at amino acid position 120 Within the heme binding
region is mutated to glycine (G), Which inactivates the

had no effect on survival from treatment With mechlore

thamine. This Was someWhat surprising given that yeast

lacking the Hpr6 homologue, Dap1p, are extremely sensitive

protein (SEQ ID NO:11).
DETAILED DESCRIPTION OF THE
INVENTION

55

25-Dx protein and its porcine homologues are microsomal

to alkylating agent MMS (Hand R A et al. Eukaryolic Cell
2003; 2: 121-32), but are relatively insensitive to doxoru

bicin (Craven, unpublished observations). Thus, it appears
that the speci?cities of Dap1p and Hpr6 dilfer, perhaps due

The Hpr6 protein (also referred to as Hpr6.6, MAPR, and
PGRMC-l) is a heme1 domain protein that is believed to
regulate the turnover of cellular metabolites. It is shoWn
herein that Hpr6 is overexpressed in cancer cells, such as
human breast, colon and thyroid tumors (but not in sarco
mas), and tumor-derived cell lines and functions therein to
protect these cells from cell death.
The Hpr6-related proteins are proposed to play a role in
metabolism and cancer for the folloWing reasons: (a) the rat

pounds are fairly speci?c to compounds that are metaboliZed
by Cyp3A4. A mutant of Hpr6, referred to herein as Hpr6
mut, inhibited survival folloWing doxorubicin treatment, but

to species differences.
60

Hpr6 expression is induced by doxorubicin and camp
tothecin, and Hpr6 induction parallels the activity of the
Ad-Hpr6-mut adenovirus to various drugs, including doxo
rubicin, camptothecin and etoposide, for example. Microar
ray analyses have identi?ed a number of proteins that are

induced by doxorubicin, including the DNA repair gene
65

XRCCl, the Fms-related tyrosine kinase, and the 268 pro
teosome regulatory sub-unit 4 (Kudoh et al. Cancer Res

2000; 60: 4161-4166) A similar analysis in patients treated

US 7,342,100 B2
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6

With doxorubicin revealed similar changes in DNA repair
genes, protein kinases, members of the proteosome pathway
(Sotiriou et al. Breast Cancer Res 2002; 4: R3-11), although
the speci?c genes di?cered from those identi?ed previously.
Hpr6 (sometimes listed in databases as “PGRMCI” for
progesterone receptor membrane component 1) Was not
present on early microarrays, perhaps due to the high G-C

In normal tissues, Hpr6 is highly expressed in liver and
kidney (Gerdes et al. Biol Chem 1998; 379: 907-11), tissues
that are directly exposed to compounds taken up by the
digestive tract and Which express proteins that neutraliZe
these compounds, such as P450 proteins (Watkins et al. Pr0c
NallAcad Sci 1985; 82: 6310-4; and Phillips et al. Pr0c Natl
Acad Sci 1985; 82: 983-987).
When overexpressed in non-sarcoma tumors, such as
breast tumor, lung tumors, ovarian tumors, colon tumors or

content in the 5' region of the gene. Our results suggest that
Hpr6 is induced as a part of a global response to neutraliZe

thyroid tumors, for example, Hpr6 protects tumor cells from
Cyp3A4 mataboliZable compounds, such as doxorubicin,
etoposide and camptothecin providing resistance to this

topoisomerase inhibitor chemotherapeutic agents such as
doxorubicin or resist cell death. It is shoWn herein, hoWever,

that overexpression of the Hpr6-mut protein overcomes this

class of chemotherapeutic drugs. Furthermore, inhibiting

response.

Hpr6 increases the ability of chemotherapeutic drugs to kill

The role for Hpr6 in providing resistance to Cyp3A4
metaboliZable anti-cancer agents is consistent With its local
iZation to the perinuclear region, Which is also the site for

cancer cells, Which makes Hpr6 a target for intervention in
cancer therapy.

numerous cytochrome P450 proteins and drug metaboliZing
proteins (Rieger et al. Cancer Res 2004; 64: 2357-64). In
addition, doxorubicin accumulates in the perinuclear region

not in sarcomas), as Well as breast tumors. It has also been

in drug-resistant cell lines (Rajagopal et al. Mal Biai Cel/

Hpr6 is overexpressed in colon and thyroid tumors (but
20

2003; 14: 3389-99), presumably sequestering the drug from
its nuclear site of action. Interestingly, cytochrome b5, the
prototype heme-1 domain protein and a relative of Hpr6,
localiZes to the endoplasmic reticulum (D’Arrigo et al. J
Biai Chern 1993; 268: 2802-8) as does the heme metabo
liZing protein heme oxygenase (Volti et al. Biachem and

Miller and E. T. Liu, personal communication). Thus, Hpr6
is Widely overexpressed in non-sarcoma cancer cells.
25

an additional membrane component in neuronal cells.

for compounds or agents that inhibit Hpr6 activity, cells that

30

Our results suggest that Hpr6 resides in the endoplasmic
reticulum, Where it binds to heme and regulates resistance to

anti-cancer agents. It is proposed that Hpr6 up-regulates the
activity of proteins that metaboliZe chemotherapeutic agents

molecule, peptide, peptoid, monoclonal or polyclonal anti
body or fragment thereof, an RNA/DNA aptamer, siRNA or
anti-sense nucleic acid that binds to Hpr6 nucleic acid and
inactivates it, or the like.
It is Well knoWn in the art that viability of a cell can be

40

under a microscope. Viable cells can be observed to have an

toreductase and that Hpr6-mut blocks this function. There is

a precedent for Hpr6 homologues acting to promote CYP

protein function. The rodent Hpr6 homologue, IZAg,

determined by contacting the cell With a dye and vieWing it
intact membrane and do not stain, Whereas dying or dead

tein Cyp51 (also knoWn as Ergllp), a highly conserved P450

cells having “leaky” membranes do stain. Incorporation of

protein. Altemately, Hpr6 could regulate the activity of an
aldoketoreductase (Peltoketo et al. J Mal Endocrin 1999; 23:
1-11) Which reduces a ketone group at the C-13 position of

doxorubicin. Through either mechanism, Hpr6 Would ulti

45

mately drive the metabolism of therapeutic agents such as

uptake or incorporation of the labeled nucleotides indicates

mut protein Would lead to cell death.
50

DNA synthesis and cell viability. In addition, colonies
formed by cells cultured in medium indicate cell groWth and
is another means to test viability of the cells.
Identi?cation and/ or observation of cells undergoing apo

substrates and associated proteins. HoWever, there is evi
dence that Hpr6 homologues function as a covalently bound

dimer. Thus, Hpr6-mut could bind directly to Wild-type
Hpr6, forming an inactive complex. Inactive homodimer

the dye by the cell indicates the death of the cell. The most
common dye used in the art for determining viability is
trypan blue. Viability of cells can also be determined by
detecting DNA synthesis. Cells can be cultured in cell

medium With labeled nucleotides (e.g., 3H thymidine). The

doxorubicin, and disruption of Hpr6 function With the Hpr6

The structural basis through Which Hpr6-mut disrupts
Hpr6 function is unknown. One likely mechanism for Hpr6
mut is competition With endogenous Hpr6 for binding to

overexpress Hpr6 are exposed to the test agent or compound
and doxorubicin or other Cyp3A4 metaboliZable anti-cancer
agent; and test agents or compounds that result in enhanced
cell death compared to cells that are exposed only to the
Cyp3A4 metabolizable anti-cancer agent are identi?ed as
anti-cancer agents. The test compound may be a small

35

such as doxorubicin, Which includes CYP3A4 or aldoke

increases CYP activity for 21-hydroxylation of progester
one. Furthermore, the yeast Dap1p protein targets the pro

Thus, Hpr6 is an excellent target for screening agents that
enhance the e?cect of anti-cancer agents. In a typical assay

Biophys Res C0mm 2004 315: 517-524). The perinuclear
staining pattern for Hpr6 resembles that reported for rodent

homologues of Hpr6 in liver, While Hpr6 homologues have

demonstrated that Hpr6 levels are elevated in lung cancer
tumor cells (Di?lippantonio, et al., Eur. Journal of Cancer
39: 1936, 2003) and some unpublished data from a microar
ray analysis shoW that it is elevated in ovarian cancer (L.

ptosis can be another method of determining cell viability.
Apoptosis is a speci?c mode of cell death recogniZed by a
55

characteristic pattern of morphological, biochemical, and
molecular changes. Cells going through apoptosis appear

formation is a common mechanism among dominant-nega

shrunken, and rounded; they also can be observed to become

tive mutants (Rishi et al. JBiai Chern 2004; 279: 11863-74;
and Zhu et al. Mal Cell Biai 2004; 24: 2673-81), including

detached from culture dish. Thermophological changes

drug resistance proteins (Kage et al. J Cancer 2002; 97:
626-30) and cytochrome proteins (Curry et al. Genomics
2004; 83: 425-38). HoWever, covalently bound dimers
betWeen endogenous Hpr6 and Hpr6-mut Would have been
detected on Western blots of infected cells (such as those in
FIG. 2), and these bands Were not observed.

Thus, Hpr6 appears to function in protecting tumor cells
from anti-cancer agents that are metaboliZable by Cyp3A4.

involve a characteristic pattern of condensation of chromatin
60

and cytoplasm Which can be readily identi?ed by micros
copy. When stained With a DNA-binding dye, such as

H33258, apoptotic cells display classic condensed and punc
tate nuclei instead of homogeneous and round nuclei.
The hallmark of apoptosis is the endonucleolysis, a
65

molecular change in Which nuclear DNA is initially
degraded at the linker sections of nucleosomes to give rise
to fragments equivalent to single and multiple nucleosomes.

US 7,342,100 B2
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When these DNA fragments are subjected to gel electro
phoresis, they reveal a series of DNA bands Which are

cell that overexpresses Hpr6 to Cyp3A4 metaboliZable drugs
When expressed therein. In a most preferred embodiment,

positioned approximately equally distant from each other on

the vector is a replication-de?cient adenoviral vector. The

the gel. The siZe difference betWeen the tWo bands next to
each other is about the length of one nucleosome (i.e., 20

vector may encode, for example, a mutant of Hpr6 that has
a mutation in the heme binding region of the gene or a

base pairs). This characteristic display of the DNA bands is

fragment of Hrp6 that interferes With the ability of Wild-type

called a DNA ladder and it indicates apoptosis of the cell.

Hpr6 to protect cells from the effects of Cyp3A4 matabo

Apoptotic cells can be identi?ed by How cytometric methods

liZable anti-cancer agents, e.g., etoposide, doxorubicin,
taxol, paclitaxol and camptothecin When expressed in the

based on measurement of cellular DNA content, increased

cells.
The present invention also provides kits for the treatment

sensitivity of DNA to denaturation, or altered light scattering
properties. These methods are Well knoWn in the art and are

Within the contemplation of the invention.
As used herein, “compound” refers to any agent, chemical
substance, or substrate, Whether organic or inorganic, or any

of non-sarcoma tumors comprising at least one Cyp3A4
metaboliZable anti-cancer agent and at least one anti-Hpr6

protein including antibodies and functional fragments
thereof, peptides, polypeptides, peptoids, and the like.

rubicin, etoposide, camptothecin, and combinations thereof.

agent. The anti-cancer agent may be for example, doxorubo
The anti-Hrp6 agent is any agent or combination of agents
that interfere With the ability of Wild-type Hpr6 to protect

Agents that inactivate Hpr6 also include mutants of Hpr6
that interfere With Wild-type Hpr6 activity When adminis
tered to cells. For example, Hpr6-mut, and other mutants of
Hpr6 that cannot bind heme are useful anti-cancer agents.
Such mutants include those that have mutations, such as

20

encoding Hpr6-mut.
The folloWing examples are presented for the illustrative

point mutations, deletions or additions, for example, to the
heme binding site of the protein, Which is shoWn in FIG. 7.
As used herein, the term “antibody” refers to an immu
noglobulin molecule With a speci?c amino acid sequence
evoked by an antigen, e.g. Hpr6 or the heme binding region

tumor cells from the killing effects of the anti-cancer agent.
For example, the anti-Hpr6 agent may be an adenoviral
vector, preferably a replication de?cient adenoviral vector

25

of Hpr6, and characterized by reacting speci?cally With the

purposes and it is to be understood that the present invention
is not limited to those precise embodiments, and that various
changes and modi?cations can be effected therein by one
skilled in the art Without departing from the scope and spirit
of the invention as de?ned by the appended claims.

antigen in some demonstrable Way. The term “antibody”

encompasses polyclonal and monoclonal antibody prepara
tions, CDR-grafted antibody preparations, as Well as prepa

EXAMPLE 1
30

rations including hybrid antibodies, altered antibodies,

Generation of a Hrp6 Mutant. Hpr6 Was cloned in tWo

F(AB)'.sub.2 fragments, F(AB) molecules, Fv fragments,

stages. First, the amino terminal 109 amino acids Were

single domain antibodies, chimeric antibodies and func
tional fragments thereof Which exhibit immunological bind
ing properties of the parent antibody molecule. The anti

primers HPRlFHA (5'-CCCGGGGGATCCGACGCCGC

ampli?ed from puri?ed MCF-7 cell genomic DNA using the
35

bodies can also be humanized.

CGAGGATGTGGTGGCG-3') (SEQ ID N016) and
HPR330R (5'-CCCATACGGCCCCTCGGGCC-3') (SEQ

The term “monoclonal antibody” is not limited to anti

bodies produced through hybridoma technology. The term
“monoclonal antibody” refers to an antibody or functional

fragment thereof that is derived from a single clone, includ
ing any eukaryotic, prokaryotic, or phage clone, and not the

CACCATGGAATCCGACTACCCCTATGAT
GTGCCCGATTACGTCGAGTCCGTCGC

40

ID N017). The former primer added a single HA epitope tag
sequence (Asp-Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala-Glu
Ser)(SEQ ID N014) to the amino terminus of the Hpr6 open

method by Which it is produced.

reading frame. The ampli?ed DNA Was subcloned into the

Test agents that are identi?ed as anti-cancer agents (re
ferred to herein as anti-Hpr6 agents) can be used to treat

then digested With BamHI and KpnI and ligated into the

TA cloning vector pCR2.l (InV1trogen; Carlsbad, Calif.),

non-sarcoma tumors. Therapeutic treatment of non-sarcoma 45

plasmid pBK-CMV (Stratagene, LaJolla, Calif.), forming

tumors comprises administration of an effective amount of

the plasmid pRC38. A fragment containing the 3' end of
Hpr6 Was ampli?ed from the plasmid IMAGE 3254089

the anti-Hpr-6 agent and a Cyp3A4 metaboliZable anti
cancer agent to a patient. In a preferred embodiment, the

(Research Genetics; Huntsville, Ala.) using the primers

anti-cancer agent is doxorubicin, although other Cyp3A4

HPR126F (5'-ACAAGATCGTGCGCGGGGA-3') (SEQ ID
N018) and HPR690R-APA (5'-TGTGGGCCCCTC

metaboliZable anti-cancer agents or combinations of agents
may be used. In one embodiment of this aspect of the
invention the anti-Hpr6 agent is a mutant form of the Hrp6
gene, such as Hprt6-mut, Which interferes With the ability of

Wild-type Hpr6 to protect cells from the effects of Cyp3A4
mataboliZable anti-cancer agents. The skilled practitioner

50

GAGAAACTTATAGCAAGTGCTC-3') (SEQ ID N019),
digested With ApaI, and inserted into the ApaI site of the

plasmid pRC38, forming the plasmid pRC40. The integrity
55

can determine the effective amount of anti-Hpr6 agent
required to induce such interference.
The anti-Hpr6 agent and anti-cancer agent may be admin
istered simultaneously, or Within a short time of one another,
e.g., about one to 24 hours. In the latter case it is preferred

3254089 (Research Genetics, Huntsville, Ala.) using the
primers HPR-Dl20G-F (5'-TACGGGCCCGAGGGGCCG
TATGGGGTCTTTGCTGGAAGAGATG
60

that the anti-Hpr6 agent is administered ?rst, but the order
of administration is not essential. Preferably, the anti-Hpr6

reading frame. The resulting plasmid, pRC42, contained the

treated. HoWever, systemic administration is also possible.
plasmid or an adenoviral vector, Which encodes Hpr6-mut or
other mutant of Hpr6 that enhances the sensitivity of a tumor

CATCCAGGGGCCTTGC-3') (SEQ ID N01l0) and HPR
690R-APA (SEQ ID N09). The resulting PCR product Was
digested With ApaI and cloned into the same site of the
plasmid pRC38, Which included the 5' end of the HPR6 open

agent is administered by direct injection into a tumor to be

The present invention also provides a vector, preferably a

of all plasmid insets Was veri?ed by automated sequencing.
The 3' end of the HPR6 open reading frame containing the
Dl20G mutation Was ampli?ed from the plasmid IMAGE
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full-length HPR6 open reading frame With the Dl20G
mutation. The HPR6-D120G open reading frame Was

excised by digestion With BamHI and XhoI and cloned into

US 7,342,100 B2
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the BglII and XhoI sites of pShuttle-CMV (provided by the

hydrosul?te, as expected (data not shoWn). We conclude that
Hpr6 is a heme-binding protein, and that Hpr6-D120G is an
inactive form of the protein.

University of North Carolina at Chapel Hill Adenoviral Core

Facility), resulting in the plasmid pRC45.

EXAMPLE 4

EXAMPLE 2

The Ad-Hpr6-mut adenovirus ef?ciently directs expres
sion of Hpr6-D120G. An adenovirus (called Ad-Hpr6-mut)
encoding the inactive Hpr6 protein Was prepared. MDA

Expression plasmids and viral preparation. The 3' end of
the HPR6 open reading frame containing the DI20G muta
tion Was ampli?ed from the plasmid IMAGE 3254089

MB-231 human breast cancer cells Were infected With the

(Research Genetics, Huntsville, Ala.) using the primers

Ad-Hpr6-mut adenovirus, resulting in ef?cient expression of
the Hpr6-mut protein (FIG. 2C, top panel, lanes 1-3).

HPR-DI20G-F and HPR-690R-APA (primer sequences
available on request). The resulting PCR product Was
digested With ApaI and cloned into the same site of the

Expression Was dependent on the dose of the virus (FIG. 2C,
top panel, lanes 1-3), While infection of MDA-MB-231 cells

plasmid pRC38 (Hand et al. Journal of Cellular Biochem

With a control Ad-LacZ adenovirus did not yield any detect

istry 2003; 90: 534-47.), Which included the 5' end of the

HPR6 open reading frame. The resulting plasmid, pRC42,

able protein expression (FIG. 2C, top panel, lane 4). At a

contained the full-length HPR6 open reading frame With the
D 120G mutation. The HPR6-DI20G open reading frame
Was excised by digestion With BamHI and XhoI and cloned

expressed relative to the endogenous Hpr6 protein (FIG. 2D,

into the BglII and XhoI sites of pShuttle-CMV (provided by

dose of 1000 pfu/cell of Ad-Hpr6-mut, Hpr6-mut Was over

20

the University of North Carolina at Chapel Hill Adenoviral

(FIG. 2D, upper panel, lane 2). We conclude that Hpr6-mut

Core Facility), resulting in the plasmid pRC45.
Fusion protein plasmids, preparation, and analysis. Hpr6

is an inactive form of Hpr6, and that overexpression of
Hpr6-mut is capable of acting as a dominant-negative form

GST fusion proteins contained amino acids 43-195 of the

Hpr6 open reading frame. Hpr6 Was ampli?ed using the

middle panel, indicated as “Hpr6-mut” and “Hpr6”, respec
tively). The identity of the Hpr6-mut protein Was con?rmed
by Western blotting With an antibody to the HA epitope tag

25

of the protein.

primers HPR+126F-Bam and HPR+566R-Xho With the
plasmid pRC40 as a template. PCR products Were cloned

EXAMPLE 5

into the pCR2.1 plasmid (InV1trogen, Carlsbad, Calif.) form
ing the plasmid pRC44. The Hpr6 fragment Was then ligated
into the Barn HI and Xho I on the plasmid pGEX-4T-I

Drug treatment, viability assays, and immunological
analyses. Doxorubicin (Sigma, St. Louis, Mo.) Was added to
30

(Amersham Biosciences, PiscataWay, N.J.), forming the
plasmid pRC46. To introduce the DI20G mutant, the plas
mid pRC46 Was digested With Apa I and Xho I and ligated
to the 260 bp Apa I-Xho I fragment of the plasmid pRC45,
forming the plasmid pGC4. The structure of all of these
plasmids Was veri?ed by automated sequencing.
Fusion protein expression Was induced With 1 mM IPTG
(Fisher) and cells Were lysed in the B-PER reagent (Pierce,
Rockford, Ill.) and bound to glutathione-agarose beads
(Pierce). At this stage, the GST-Hpr6-bound columns Were
visibly broWn due to bound heme, While the GST-Hpr6

sity of North Carolina at Chapel Hill) or camptothecin
(Sigma) for 72 hours. Trypan blue and MTT assays Were
35

2003; 90: 534-47). Western blots of cultured cells and

Journal of Cellular Biochemistry 2003; 90: 534-47; Yang et
40

al. Tumor Biology 2003; 24: 61-9). The antibodies used Were

as folloWs: anti-HA (HAll, BAbCo, Berkeley, Calif.), tubu
lin (Fisher), and Hpr6 (Meyer et al. Steroids 1998; 63:
111-6). Cells Were visualiZed using a VistaVision inverted
microscope attached to a Sony DCS F717 digital camera
45

(VWR, Batavia, Ill.). For immuno?uorescence, MCF-7/
vector and MCF-7/Hpr6 cells (Hand et al. Journal of Cel
lular Biochemistry 2003; 90: 534-47) Were ?xed With 3.7%

thrombin for tWo hours, and absorbance at 400 nm Was

determined using a Spectronics Genesys 5 spectrophotom

formaldehyde, permeabiliZed With 0.1% Triton X-100,

eter (Spectronics Instruments, Rochester, N.Y.).
EXAMPLE 3

performed using standard techniques as previously
described (Hand et al. Journal of Cellular Biochemistry
tumors Were performed as described previously (Hand et al.

DI20G-bound columns Were White due to the inability of

this mutant to bind heme. After estimating protein quantity
by SDS-PAGE electrophoresis, 100/-1 g of Hpr6 or Hpr6
DI20G proteins Were liberated by digestion With I U of

culture media and incubated for ?ve days. Cells Were

incubated With hydrogen peroxide (Fisher), mechlore
thamine (kindly provided by Dr. Robert OrloWski, Univer

50

blocked With 10% normal goat serum, and incubated With
the HAll monoclonal antibody. Cells Were then Washed,
incubated With a FITC-Iabeled anti-mouse secondary anti

body (Santa CruZ Biotechnology, Santa CruZ, Calif.),

Hpr6 binds to heme, and the D120G mutation in the

heme-1 domain blocks heme-binding activity. Hpr6 is

Washed, mounted, and visualiZed using a Zeiss ?uorescent

highly conserved With a group of proteins that share the
sequence FYGP-x-GPY-x-x FAG-x-DASR-x-LA (SEQ ID
NO: 5). AnAsp-to-Gly mutation in this sequence inactivates

microscope.
55

Ad-Hpr6-mut synergiZes With doxorubicin in MDA-MB

the yeast Dap1p protein (R. Craven, unpublished observa

231 breast cancer cells. The effect of the Ad-Hpr6-mut
adenovirus in response to chemotherapy Was analyZed for

tions). An analogous D120G mutation Was made in Hpr6

tWo reasons. First, the budding yeast homologue of Hpr6

and puri?ed the Hpr6 and Hpr6-D120G proteins (FIG. 2A),
then tested the proteins for heme binding (FIG. 2B). Hpr6

60

controls resistance to damaging agents. Second, We found
that Hpr6 expression is induced in response to the chemo

bound ef?ciently to heme based on absorbance at 400 nm

therapeutic drugs doxorubicin and camptothecin in the

(FIG. 2B, left column), and this activity Was absent in the

breast cancer cell line MDA-MB-231 (FIG. 1B), as Well as

Hpr6-D120G protein (FIG. 2B, right column). The measure

in MCF-7 cells (data not shoWn). In contrast to these
?ndings, Hpr6 expression Was not induced in response to the

ment Was performed in triplicate, and the difference betWeen

Hpr6 and Hpr6-D120G absorbance Was statistically signi?

65

chemotherapeutic drugs cisplatinum and mechlorethamine

cant (P:0.03). The absorption curve for Hpr6 shifted from

or folloWing treatment With hydrogen peroxide (data not

400 nm to 420 nm When the protein Was treated With sodium

shoWn).

US 7,342,100 B2
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Ad-Hpr6-mut infection triggered cell death in MDA-MB
231 cells following doxorubicin treatment (FIG. 3). Doxo
rubicin treatment caused signi?cantly greater lethality in
Ad-Hpr6-mut-infected cells (FIG. 3A-D, dashed lines) com

25-100 uM hydrogen peroxide for 72 hours died to the same
extent When infected With Ad-LacZ or Ad-Hpr6-mut (data
not shoWn). We also tested the extent to Which Ad-Hpr6-mut

pared to cells infected With a control Ad-LacZ adenovirus

peutic drugs. MDA-MB-231 cells Were infected With Ad
LacZ or Ad-Hpr6-mut and treated With the alkylating agent
mechlorethamine, and Hpr6 -mut expression had no effect on
viability, (data not shoWn). Similar results Were obtained

sensitiZed MDA-MB-23 I cells to additional chemothera

(FIG. 3A-D, solid lines), and loss of viability increased
proportionally With doxorubicin dose (FIG. 3A). Loss of
viability Was highly signi?cant at a dose of 0.5 (100%

viability for Ad-LacZ compared to 81% for Ad-Hpr6-mut,
P:0.0003), 1 (Ad-LacZ, 69% compared to Ad-Hpr6-mut,
7%; P:0.0002), and 1.5 uM doxorubicin (Ad-LacZ, 29%
viability compared to 0% for Ad-Hpr6-mut; P:0.008). In the

With cisplatinum (data not shoWn). We conclude that the
effects of Ad-Hpr6-mut are relatively speci?c and do not
include all classes of damaging agents and drugs.
Because doxorubicin induces resistance through activa
tion of multidrug transporters, it Was believed possible that

absence of doxorubicin, the Ad-Hpr6-mut adenovirus had no
detectable effect on tumor cell survival or proliferation (FIG.
3A-C, 0 dose of doxorubicin). Viability Was also measured

Hpr6 could act as a membrane-associated drug transport
protein. To test this possibility, We infected MDA-MB-231
cells With Ad-LacZ or Ad-Hpr6-mut, then treated them With
doxorubicin and examined doxorubicin accumulation by

by trypan blue assay, and as expected, Ad-Hpr6-mut-in
fected cells Were more sensitive to doxorubicin than Ad

LacZ-infected cells (FIG. 3B, 1 uM dose of doxorubicin,

?uorescent microscopy 2 hours later. This approach has been

P:0.0006).
20

previously used to examine the effect of P-glycoprotein on
doxorubicin accumulation in breast cancer cells (Wu H et al.

25

gies of Ad-LacZ- and Ad-Hpr6-mut-infected cells Were
similar (FIG. 4B, upper panels), no difference in doxorubicin
accumulation in Ad-LacZ vs. Ad-Hpr6-mut-infected cells
Was detected (FIG. 4B, bottom panels). Doxorubicin con

Doxorubicin-mediated cell death Was dependent on the

Cancer Research 2003; 63: 1515-9). The cellular morpholo

dose of the Ad-Hpr6-mut adenovirus (FIG. 3C). At a ?xed
dose of 1 uM doxorubicin, increased concentrations of the
Ad-Hpr6-mut adenovirus increased cell death. There Was no

signi?cant loss ofviability at a dose of 500 pfu/cell, but loss
of viability Was highly signi?cant at a dose of 1000 (70%

viability for Ad-LacZ compared to 7% for Ad-Hpr6-mut,

centrations Were also measured after 24 hours of treatment

P:0.0002), and 2000 (50% viability for Ad-LacZ compared
to 2% for Ad-Hpr6-mut, P:0.0001) pfu/cell Ad-Hpr6-mut.

by ?uorescence-activated cell sorting (F ACS) and no dif
ferences in doxorubicin levels Were detected (data not

shoWn). This result Was consistent With the ?nding that

Thus, Hpr6 is a mediator of resistance to doxorubicin in
MDA-MB-231 breast cancer cells.

30

A number of chemotherapeutic drugs target topoi
somerases. The ability of Ad-Hpr6-mut to regulate survival
folloWing treatment With the drugs etoposide and camptoth

Hpr6 is unlikely to function as a membrane-associated multi

ecin Was tested. MDA-MB-231 cells Were infected With

Ad-LacZ or Ad-Hpr6-mut and treated With 125-1000 nM

35

camptothecin, a topoisomerase I inhibitor. Synergism
betWeen Ad-Hpr6-mut and camptothecin Was signi?cant at
40

(University of North Carolina at Chapel Hill) and Were
maintained in Dulbecco’s Modi?ed Eagle Medium With

20%:2 for Ad-Hpr6-mut, P:0.009). Thus, Hpr6-mut sensi

10% Serum Supreme (Fisher, Chicago, Ill.) and penicillin

tiZes breast cancer cells to multiple topoisomerase inhibi
45

Doxorubicin frequently induces cell death via the apop
totic pathWay. We detected rounded cells in MDA-MB-231
cells infected With Ad-Hpr6-mut and treated With doxoru
bicin, although the majority of the cells had a Wasted,

necrotic morphology (FIG. 4A, right panel). These cells

90: 534-47, incorporated herein in its entirety), and MCF-7
cells Were maintained in Minimal Essential Medium con
50

taining 10% fetal bovine serum and antibiotics.

Because of the role of Hpr6 in chemotherapeutic resis
tance, the expression of Hpr6 in clinical breast tumor
samples Was analyZed. Hpr6 expression Was determined in

(FIG. 4A, left panel). In spite of the fact the cells Were
rounded, We Were unable to detect classical markers of

pairs of non-malignant breast tissue and adjacent breast
55

DNA, or nuclear condensation. We conclude that Hpr6-mut
infection induces necrotic cell death in cells treated With
doxorubicin.
EXAMPLE 6

and streptomycin at 370 C. in 5% CO2 in air. MCF-7 cells
engineered to over-express Hpr6 have been described pre

viously (Hand et al. Journal of Cellular Biochemistry 2003;

Were less evident in cells infected With a control adenovirus

apoptosis, including cleavage of PARP, the focal adhesion
kinase (F AK), endonucleolytic cleavage of chromosomal

Hpr6 is over-expressed in breast tumors.
Cell lines, culturing, and infection. MDA-MB-23 Ihuman
breast cancer cells Were a kind gift from Dr. Carolyn Sartor

side. Ad-Hpr6-mut caused a signi?cant increase in cell death
at doses of 10 uM etoposide (27%:08 for Ad-LacZ vs.

tors.

drug transport protein.
EXAMPLE 7

125 nM (FIG. 3D, 79%:9 for Ad-LacZ vs. 48%:2 for
Ad-Hpr6-mut, P:0.005). We also detected a less dramatic

but signi?cant synergism betWeen Ad-Hpr6-mut and etopo

Ad-Hpr6-mut does not synergiZe With mechlorethamine,
because membrane drug transporters usually act on multiple
drugs. In addition, We subsequently found that Hpr6 does
not localiZe to the cell membrane (see Example 7). Thus,

60

tumors from the same patients. Hpr6 Was expressed Weakly
in 9 separate non-malignant breast tissue samples (3 are
shoWn in FIG. 5A, lanes 1, 3, and 5) and Was over-expressed
in tumors from 7 of these patients (FIG. 5A, examples in

lanes 2 and 6). Hpr6 over-expression in tumors ranged from
strong (FIG. 5A, lane 2) to moderate (FIG. 5A, lane 6), and
Hpr6 Was not over-expressed in some tumors (FIG. 5A, lane

4). Hpr6 Was also highly expressed in 4/11 non-matched
breast tumor samples (FIG. 5B). Taking all of the samples
together, it Was found that Hpr6 Was highly expressed in

Ad-Hpr6-mut infection does not cause cell death from

peroxide or other chemotherapeutic drugs. Doxorubicin
causes toxicity through the creation of reactive oxygen

species and by inhibiting topoisomerase activity. We tested
Whether Ad-Hpr6-mut infection altered the response of
MDA-MB-231 cells to oxidative damage. Cells treated With

65

6/ 18 breast tumors and Was moderately expressed in 5/ 18

tumors (FIG. 5C, right). LoW expression levels ere found in
6/ 18 breast tumors, and a single tumor had no detectable

US 7,342,100 B2
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expression of Hpr6 (FIG. 5C, right). In all cases, non
malignant breast tissues exhibited Weak but detectable

Hpr6 Were stained With a monoclonal antibody to the

expression of Hpr6 (FIG. 5C, left). Thus, Hpr6 is over
expressed in breast cancer.
The sub-cellular localization of Hpr6 Was determined.
The antibody used for Western blotting Was raised to a
peptide sequence at the Hpr6 amino terminus, and no

staining Was detected With this antibody (data not shoWn).
MCF-7 breast cancer cells expressing an epitope-tagged

epitope tag by immuno?uorescence. No staining Was detect
able in MCF-7 cells harboring a control plasmid (FIG. 6,
panel 2), While the majority of MCF-7/Hpr6 cells exhibited

sharp perinuclear staining (FIG. 6, panels 4 and 6). This
perinuclear staining resembled that of the endoplasmic
reticulum dye BODIPY Brefeldin A (Hand and Craven,
unpublished observations), suggesting that Hpr6 localiZes to
the endoplasmic reticulum.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS :

<211> LENGTH:

1O

195

<2l3> ORGANISM: Homo sapiens
<400> SEQUENCE:

1

Met Ala Ala Glu Asp Val Val Ala Thr Gly Ala Asp Pro Ser Asp Leu
1

5

1O

15

Glu Ser Gly Gly Leu Leu His Glu Ile Phe Thr Ser Pro Leu Asn Leu
20

25

30

Leu Leu Leu Gly Leu Cys Ile Phe Leu Leu Tyr Lys Ile Val Arg Gly
35

4O

45

Asp Gln Pro Ala Ala Ser Gly Asp Ser Asp Asp Asp Glu Pro Pro Pro
50

55

6O

Leu Pro Arg Leu Lys Arg Arg Asp Phe Thr Pro Ala Glu Leu Arg Arg
80

Phe Asp Gly Val Gln Asp Pro Arg Ile Leu Met Ala Ile Asn Gly Lys
85

90

Val Phe Asp Val Thr Lys Gly Arg Lys Phe Tyr Gly Pro Glu Gly Pro
100

105

110

Tyr Gly Val Phe Ala Gly Arg Asp Ala Ser Arg Gly Leu Ala Thr Phe
115

120

125

Cys Leu Asp Lys Glu Ala Leu Lys Asp Glu Tyr Asp Asp Leu Ser Asp
130

135

140

Leu Thr Ala Ala Gln Gln Glu Thr Leu Ser Asp Trp Glu Ser Gln Phe
145

150

155

160

Thr Phe Lys Tyr His His Val Gly Lys Leu Leu Lys Glu Gly Glu Glu
165

170

Pro Thr Val Tyr Ser Asp Glu Glu Glu Pro Lys Asp Glu Ser Ala Arg
180

185

190

Lys Asn Asp
195

<211> LENGTH:

619

<2l3> ORGANISM: Homo sapiens
<400> SEQUENCE: 2

atggctgccg aggatgtggt ggcgactggc gccgacccaa gcgatctgga gagcggcggg

6O

ctgctgcatg agattttcac gtcgccgctc aacctgctgc tgcttggcct ctgcatcttc

120

ctgctctaca agatcgtgcg cggggaccag ccggcggcca gcggcgacag cgacgacgac

180

gagccgcccc ctctgccccg cctcaagcgg cgcgacttca cccccgccga gctgcggcgc

240
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18
—cont inued

Phe Tyr Gly Pro Xaa Gly Pro Tyr Xaa Xaa Phe Ala Gly Xaa Asp Ala
l

Ser Arg Xaa Leu Ala

SEQ ID NO 6
LENGTH: 90
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically Synthesized
SEQUENCE: 6

cccgggggat ccgacgccgc caccatggaa tccgactacc cctatgatgt gcccgattac

gtcgagtccg tcgccgagga tgtggtggcg

9O

SEQ ID NO '7
LENGTH: 20
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically Synthesized
SEQUENCE: '7

cccatacggc ccctcgggcc
SEQ ID NO 8
LENGTH: 19
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically Synthesized
SEQUENCE: 8

acaagatcgt gcgcgggga

19

SEQ ID NO 9
LENGTH: 34
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically Synthesized
SEQUENCE: 9

tgtgggcccc tcgagaaact tatagcaagt gctc

34

SEQ ID NO 10
LENGTH: 59
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically Synthesized
SEQUENCE: l0

tacgggcccg aggggccgta tggggtcttt gctggaagag atgcatccag gggccttgc

What is claimed is:

1. An isolated polypeptide having the amino acid
sequence of SEQ ID NOzll.
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